Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism (FOR-HYPO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04126941|
Recruitment Status : Unknown
Verified October 2019 by Hospices Civils de Lyon.
Recruitment status was: Recruiting
First Posted : October 15, 2019
Last Update Posted : October 15, 2019
Pediatric hypoparathyroidism is an orphan disease. Conventional management combines native and active vitamin D, calcium supplementation and sometimes phosphate binders, with the risk of long term hypercalciuria, nephrocalcinosis and further renal impairment. The use of teriparatide has been reported in adults (daily or bi-daily subcutaneous infusions) and in children (rather continuous subcutaneous infusion) as second-line therapy.
The objective of this study is to obtain efficacy and safety data on the use of teriparatide in children with hypoparathyroidism to improve our knowledge of their management.
|Condition or disease||Intervention/treatment|
|Hypoparathyroidism||Other: Serum calcium concentrations results|
|Study Type :||Observational|
|Estimated Enrollment :||9 participants|
|Official Title:||Bi-daily Injection of Subcutaneous Teriparatide in Children With Hypoparathyroidism: Single-center Experience|
|Actual Study Start Date :||June 1, 2019|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||December 2020|
Patients with hypoparathyroidism treated by teriparatide
Other: Serum calcium concentrations results
To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
- Serum calcium concentration [ Time Frame: 3 months after treatment initiation ]
- Serum calcium concentration [ Time Frame: 1 month after treatment initiation ]
- Serum calcium concentration [ Time Frame: 6 months after treatment initiation ]
- Serum calcium concentration [ Time Frame: 12 months after treatment initiation ]
- Serum calcium concentration [ Time Frame: 3 years after treatment initiation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04126941
|Contact: Justine BACCHETTA, MD||4 27 85 61 30 ext +email@example.com|
|Contact: Sacha FLAMMIER, PHD||4 27 85 66 69 ext +firstname.lastname@example.org|
|Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant||Recruiting|
|Contact: Justine BACCHETTA, MD 4 27 85 61 30 ext +33 email@example.com|